China BioMed Conference Facilitates Cross-Border Deals Between Nanjing and Hong Kong
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
What happened
The China BioMed Innovation and Investment Conference concluded in Nanjing, gathering over 2,000 participants from more than 100 organizations. Co-hosted by the China Pharmaceutical Innovation and Research Development Association and Hong Kong Exchanges and Clearing Limited, the event facilitated cross-border collaborations and out-licensing deals. The conference noted that the total value of out-licensing deals exceeded US$130 billion.
From finanznachrichten.de
Why it matters
The biopharmaceutical industry has been designated an emerging pillar industry, supported by strong policy. The conference highlighted that 60 Class 1 innovative drugs were approved in the first three quarters of this year. This growth is supported by deepening overseas expansion models and increased integration of AI in drug discovery.
From finanznachrichten.de
Who's involved
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- JiangsuSpeculative
Jiangsu might see increased investment and industrial growth in its province.
- mainland ChinaSpeculative
mainland China's biopharma sector might see increased global investment and industrial confidence.
- GuangdongSpeculative
Guangdong might experience increased supply chain activity due to the biopharma boom.
Keep exploring
The entities involved
-
Nanjing
capital city of Jiangsu Province, China, former capital of the Republic of China and China's Ming dynasty
-
Hong Kong
city and special administrative region of China